Protagonist Therapeutics (PTGX) FDA announcement summary

Introduction and purpose

• FDA approved MIMRYLO (rusfertide), a first-in-class hepcidin mimetic peptide, for treating erythrocytosis in adults with polycythemia vera (PV), marking a significant milestone and the second major drug approval for the company this year.

• MIMRYLO is the first and only hepcidin mimetic approved for this indication, offering a novel mechanism to control hematocrit, reduce phlebotomy burden, and improve fatigue in PV patients.

Details of approval or decision

• FDA approval was granted in August 2026 following successful completion of pivotal Phase 3 VERIFY study, which met its primary and all key secondary endpoints.

• MIMRYLO is indicated for adults with PV to control erythrocytosis and maintain hematocrit below 45%, with a broad label allowing use as monotherapy or in combination with other PV therapies.

• The drug received orphan drug, fast track, breakthrough therapy, and priority review designations.

• FDA approval triggers milestone payments up to $275M and tiered royalties between 14%-29%.

• Takeda will commercialize MIMRYLO under a worldwide license and collaboration agreement.

Impact on industry and stakeholders

• MIMRYLO is expected to shift the PV treatment paradigm, offering a targeted approach compared to current standards like phlebotomy and cytoreductive therapies, and addresses a significant unmet need with ~78% of PV patients having uncontrolled hematocrit despite current treatments.

• The broad label and clean safety profile are anticipated to drive rapid adoption across all PV patient segments.

• Projected peak sales are $1–2 billion, with milestone and royalty payments supporting further R&D and potential capital return.

• Approval validates peptide-centric drug discovery and supports further pipeline development.

• Provides a new treatment option for patients inadequately managed by current standard of care.